Vialwirebiotech, curated
November 21, 2026, 8:18 AM
November 3, 2026
- 8:00 AM · BioWorld8:00 AMPaulex to conduct first-in-human study of PAL-119 for diabetes — BioWorld
- 8:00 AM · BioWorld8:00 AMFinancings: GPN raises $10M to advance lead vaccine — BioWorld
- 8:00 AM · BioWorld
- 8:00 AM · BioWorld
- 8:00 AM · BioWorld8:00 AMShanghai Yiweikang discovers new Topo I inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMFinancing at Specific Biologics to advance ALS gene-editing therapy — BioWorld
- 8:00 AM · BioWorld8:00 AMAbbvie builds migraine pipeline with $757M Brise deal — BioWorld
- 4:45 AM · FT — Pharmaceuticals4:45 AMCinven to buy menopause specialist Theramex in €2.6bn deal — FT — Pharmaceuticals
- 4:37 AM · Pharmaceutical Technology4:37 AMBavarian Nordic secures four-year UK vaccine supply deal — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMCasZyme and Cirena to collaborate on developing longer guide RNAs — Drug Discovery World
- 3:00 AM · SCMP — Tech3:00 AMChinese drug iza-bren doubles lung cancer survival window in phase 3 trial — SCMP — Tech
November 2, 2026
- 12:07 PM · BioPharma Dive12:07 PMKaryopharm, deep in debt, to sell itself in bankruptcy — BioPharma Dive
- 11:13 AM · STAT News
- 11:00 AM · BioWorld11:00 AMPartial hold of Bright Minds’ DEE drug sends shares plummeting — BioWorld
- 11:00 AM · BioWorld11:00 AMB7-H3 ADCs shine as Kodiak, Definium report phase III wins — BioWorld
- 11:00 AM · BioWorld11:00 AMChina’s IITs the ‘buzzword of the year’ — BioWorld
- 11:00 AM · BioWorld11:00 AMBids in desmoid buoyed by ESMO data — BioWorld
- 9:27 AM · Drug Discovery World9:27 AMOpentrons announces $40m Series E funding round — Drug Discovery World
- 9:23 AM · Drug Discovery World9:23 AMFirst patients receive mRNA therapy for tumour-selective activation — Drug Discovery World
- 8:00 AM · BioWorld8:00 AMQuantx Biosciences US details new IL-17A/A and IL-17A/F inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMChia Tai Tianqing Pharmaceutical Group discovers new POLθ inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMBI-1703880 boosts radiotherapy antitumor activity — BioWorld
- 8:00 AM · BioWorld8:00 AMOric Pharmaceuticals describes new androgen receptor-targeting degraders — BioWorld
- 8:00 AM · BioWorld8:00 AMPreclinical data on EMU-003, a gene therapy for Dravet syndrome — BioWorld
- 8:00 AM · BioWorld8:00 AMNimbus Selene discloses new SLC15A4 inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMEos Senolytix reports interim aged rat findings for PTC-2105 — BioWorld
- 8:00 AM · BioWorld8:00 AMHefei Amvite Pharmaceutical patents new GHS receptor agonists — BioWorld
- 4:55 AM · Pharmaceutical Technology4:55 AMPelthos and Castle Creek plan merger to target skin diseases — Pharmaceutical Technology
- 4:39 AM · Pharmaceutical Technology4:39 AMInovio’s Voceryq receives FDA accelerated approval for RRP — Pharmaceutical Technology
- 4:30 AM · STAT News
November 1, 2026
- 7:30 PM · SCMP — Tech7:30 PMDrug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner — SCMP — Tech